A Brief Review on the Role of Vesicular Monoamine Transporter<sub>2</sub> Inhibitors in Hyperkinetic Movement Disorders.
Ali Nikkhah
Abstract
) inhibitors (Tetrabenazine, Deutetrabenazine, and Valbenazine) are new agents introduced in the last decade for treating some of movement disorders, in particular tardive dyskinesia, Huntington chorea, and Tourette syndrome. In this brief review, we discussed the role of these drugs in managing hyperkinetic movement disorders.
Topics & Concepts
Movement disordersMonoamine neurotransmitterNeuroscienceTetrabenazineMovement (music)PharmacologyMedicinePsychologyInternal medicineDopamineSerotoninPhysicsReceptorAcousticsDiseaseNeurological disorders and treatmentsGenetic Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments